Local chemotherapy

PreclinicalSmall molecule

Local chemotherapy is one of 56 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Prostate AdenocarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

57 competitors in Prostate Adenocarcinoma

#DrugCompanyPhaseTrials

Lupron

Sun Pharmaceutical Industries, Inc.

Approved

3 2

Erleada

Johnson & Johnson

Approved

3 3

Nubeqa

Bayer

Approved

1 4

Xtandi

Astellas

Approved

1 5

Firmagon

Ferring

Approved

5 6

Casodex

IIstituto Clinico Humanitas

Approved

5 7

Thalomid

Nexavar

Jevtana

Verzenio

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Adenocarcinoma1 trial

Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies

Active, not recruiting·UUniversity Hospital, Rouen··NCT03611686·219 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Local chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Local chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Local chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Rouen

Local chemotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News